Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diacerein for kidney and metabolic outcomes in type 2 diabetes with chronic kidney disease
RBR-2tfwq3Phase 3Completed
- Sponsor
- Universidade Federal do Rio Grande do Sul
- Start
- Mar 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of diacerein in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and chronic kidney disease (CKD) (2 arms), sponsored by Universidade Federal do Rio Grande do Sul. Primary endpoint: Kidney function alteration. Started Mar 2014; status: completed.
02
Drugs
diacerein
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosischronic kidney disease (CKD)
Beyond the preview
Go deeper on RBR-2tfwq3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2tfwq3.